CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Including Information on Overdiagnosis in Shared Decision Making : A Review of Prostate Cancer Screening Decision Aids
Authors
Katy J.L. Bell
Paul Glasziou
+4 more
Thanya I. Pathirana
Kristen Pickles
Jarno M. Riikonen
Kari A.O. Tikkinen
Publication date
1 January 2022
Publisher
Doi
Cite
View
on
PubMed
Abstract
Publisher Copyright: © The Author(s) 2022.Background. Overdiagnosis is an accepted harm of cancer screening, but studies of prostate cancer screening decision aids have not examined provision of information important in communicating the risk of overdiagnosis, including overdiagnosis frequency, competing mortality risk, and the high prevalence of indolent cancers in the population. Methods. We undertook a comprehensive review of all publicly available decision aids for prostate cancer screening, published in (or translated to) the English language, without date restrictions. We included all decision aids from a recent systematic review and screened excluded studies to identify further relevant decision aids. We used a Google search to identify further decision aids not published in peer reviewed medical literature. Two reviewers independently screened the decision aids and extracted information on communication of overdiagnosis. Disagreements were resolved through discussion or by consulting a third author. Results. Forty-one decision aids were included out of the 80 records identified through the search. Most decision aids (n = 32, 79%) did not use the term overdiagnosis but included a description of it (n = 38, 92%). Few (n = 7, 17%) reported the frequency of overdiagnosis. Little more than half presented the benefits of prostate cancer screening before the harms (n = 22, 54%) and only 16, (39%) presented information on competing risks of mortality. Only 2 (n = 2, 5%) reported the prevalence of undiagnosed prostate cancer in the general population. Conclusion. Most patient decision aids for prostate cancer screening lacked important information on overdiagnosis. Specific guidance is needed on how to communicate the risks of overdiagnosis in decision aids, including appropriate content, terminology and graphical display. Most patient decision aids for prostate cancer screening lacks important information on overdiagnosis. Specific guidance is needed on how to communicate the risks of overdiagnosis.Peer reviewe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Trepo - Institutional Repository of Tampere University
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:trepo.tuni.fi:10024/143271
Last time updated on 09/11/2022
Helsingin yliopiston digitaalinen arkisto
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:helda.helsinki.fi:10138/35...
Last time updated on 12/03/2023
Sydney eScholarship
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ses.library.usyd.edu.au:21...
Last time updated on 20/03/2023
PubMed Central
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pubmedcentral.nih.gov:9558...
Last time updated on 24/11/2022
Bond University Research Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:https://pure.bond.edu.au/:...
Last time updated on 30/10/2022